The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia

PURPOSE: Refractory pediatric leukemia remains one of the leading causes of death in children. Intensification of current chemotherapy regimens to improve the outcome in these children is often limited by the effects of drug resistance and cumulative toxicity. Hence, the search for newer agents and...

Descripción completa

Detalles Bibliográficos
Autores principales: Meier-Stephenson, Vanessa, Riemer, Justin, Narendran, Aru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440076/
https://www.ncbi.nlm.nih.gov/pubmed/28553123
http://dx.doi.org/10.2147/OTT.S136484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440076/
https://www.ncbi.nlm.nih.gov/pubmed/28553123
http://dx.doi.org/10.2147/OTT.S136484

Ejemplares similares